nach oben

Breast Cancer Research and Treatment

Erschienen in:

13.10.2018 | Preclinical study

Mucin 2 (MUC2) modulates the aggressiveness of breast cancer

verfasst von: Anna Astashchanka, Thomas M. Shroka, Britta M. Jacobsen

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Tumors that secrete large volumes of mucus are chemotherapy resistant, however, mechanisms underlying this resistance are unknown. One protein highly expressed in mucin secreting breast cancers is the secreted mucin, Mucin 2 (MUC2). While MUC2 is expressed in some breast cancers it is absent in normal breast tissue, implicating it in breast cancer. However, the effects of MUC2 on breast cancer are largely unknown. This study examined the role of MUC2 in modulating breast cancer proliferation, response to chemotherapy and metastasis.

Methods

Using patient derived xenografts we developed two novel cell lines, called BCK4 and PT12, which express high levels of MUC2. To modulate MUC2 levels, BCK4 and PT12 cells were engineered to express shRNA targeted to MUC2 (shMUC2, low MUC2) or a non-targeting control (shCONT, high MUC2) and proliferation and apoptosis were measured in vitro and in vivo. BCK4 cells with shCONT or shMUC2 were labeled with GFP-luciferase and examined in an experimental metastasis model; disease burden and site specific dissemination were monitored by intravital imaging and fluorescence guided dissection, respectively.

Results

Proliferation decreased in BCK4 and PT12 shMUC2 cells versus control cells both in vitro and in vivo. Chemotherapy induced minimal apoptosis in control cells expressing high MUC2 but increased apoptosis in shMUC2 cells containing low MUC2. An experimental metastasis model showed disease burden decreased when breast cancer cells contained low versus high MUC2. Treatment with Epidermal Growth Factor (EGF) increased MUC2 expression in BCK4 cells; this induction was abolished by the EGF-receptor inhibitor, Erlotinib.

Conclusions

MUC2 plays an important role in mediating proliferation, apoptosis and metastasis of breast cancer cells. MUC2 may be important in guiding treatment and predicting outcomes in breast cancer patients.

Nur mit Berechtigung zugänglich

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30. https://doi.org/10.3322/caac.21332 PubMedCrossRef

Kufe DW (2009) Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 9(12):874–885. https://doi.org/10.1038/nrc2761 PubMedPubMedCentralCrossRef

Mukhopadhyay P, Chakraborty S, Ponnusamy MP, Lakshmanan I, Jain M, Batra SK (2011) Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim Biophys Acta 1815(2):224–240. https://doi.org/10.1016/j.bbcan.2011.01.001 PubMedPubMedCentralCrossRef

Yang C, Murray JL, Ibrahim NK (2018) MUC1 and cancer immunotherapy, vol 1. Elsevier Inc., Amsterdam, pp 225–240

Macha MA, Krishn SR, Jahan R, Banerjee K, Batra SK, Jain M (2015) Emerging potential of natural products for targeting mucins for therapy against inflammation and cancer. Cancer Treat Rev 41(3):277–288. https://doi.org/10.1016/j.ctrv.2015.01.001 PubMedPubMedCentralCrossRef

Diaz LK, Wiley EL, Morrow M (2001) Expression of epithelial mucins Muc1, Muc2, and Muc3 in ductal carcinoma in situ of the breast. Breast J 7(1):40–45PubMedCrossRef

Do SI, Kim K, Kim DH, Chae SW, Park YL, Park CH, Sohn JH (2013) Associations between the expression of mucins (MUC1, MUC2, MUC5AC, and MUC6) and clinicopathologic parameters of human breast ductal carcinomas. J Breast Cancer 16(2):152–158. https://doi.org/10.4048/jbc.2013.16.2.152 PubMedPubMedCentralCrossRef

Matsukita S, Nomoto M, Kitajima S, Tanaka S, Goto M, Irimura T, Kim YS, Sato E, Yonezawa S (2003) Expression of mucins (MUC1, MUC2, MUC5AC and MUC6) in mucinous carcinoma of the breast: comparison with invasive ductal carcinoma. Histopathology 42(1):26–36PubMedCrossRef

Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC, Robertson JF, Ellis IO (2005) Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 18(10):1295–1304. https://doi.org/10.1038/modpathol.3800445 PubMedCrossRef

10.

Chu JS, Chang KJ (1999) Mucin expression in mucinous carcinoma and other invasive carcinomas of the breast. Cancer Lett 142(1):121–127. doi:S0304-3835(99)00161-5 [pii]PubMedCrossRef

11.

Walsh MD, McGuckin MA, Devine PL, Hohn BG, Wright RG (1993) Expression of MUC2 epithelial mucin in breast carcinoma. J Clin Pathol 46(10):922–925PubMedPubMedCentralCrossRef

12.

Xu Y, Kimura N, Yoshida R, Lin H, Yoshinaga K (2001) Immunohistochemical study of Muc1, Muc2 and human gastric mucin in breast carcinoma: relationship with prognostic factors. Oncol Rep 8(5):1177–1182PubMed

13.

Adsay NV, Merati K, Nassar H, Shia J, Sarkar F, Pierson CR, Cheng JD, Visscher DW, Hruban RH, Klimstra DS (2003) Pathogenesis of colloid (pure mucinous) carcinoma of exocrine organs: Coupling of gel-forming mucin (MUC2) production with altered cell polarity and abnormal cell-stroma interaction may be the key factor in the morphogenesis and indolent behavior of colloid carcinoma in the breast and pancreas. Am J Surg Pathol 27(5):571–578PubMedCrossRef

14.

Patel DS, Khandeparkar SGS, Joshi AR, Kulkarni MM, Dhande B, Lengare P, Phegade LA, Narkhede K (2017) Immunohistochemical study of MUC1, MUC2 and MUC5AC expression in primary breast carcinoma. J Clin Diagn Res 11(4):EC30–EC34. https://doi.org/10.7860/JCDR/2017/26533.9707 PubMedPubMedCentralCrossRef

15.

Kasashima S, Kawashima A, Zen Y, Ozaki S, Kobayashi M, Tsujibata A, Minato H (2007) Expression of aberrant mucins in lobular carcinoma with histiocytoid feature of the breast. Virchows Arch 450(4):397–403. https://doi.org/10.1007/s00428-007-0381-z PubMedCrossRef

16.

Lesuffleur T, Porchet N, Aubert JP, Swallow D, Gum JR, Kim YS, Real FX, Zweibaum A (1993) Differential expression of the human mucin genes MUC1 to MUC5 in relation to growth and differentiation of different mucus-secreting HT-29 cell subpopulations. J Cell Sci 106(Pt 3):771–783PubMed

17.

Nagao T, Kinoshita T, Hojo T, Tsuda H, Tamura K, Fujiwara Y (2012) The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics. Breast 21(3):289–295. https://doi.org/10.1016/j.breast.2011.12.011 PubMedCrossRef

18.

Munzone E, Giobbie-Hurder A, Gusterson BA, Mallon E, Viale G, Thurlimann B, Ejlertsen B, MacGrogan G, Bibeau F, Lelkaitis G, Price KN, Gelber RD, Coates AS, Goldhirsch A, Colleoni M, International Breast Cancer Study G, the BIGCG (2015) Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1–98 trial. Ann Oncol 26(12):2442–2449. https://doi.org/10.1093/annonc/mdv391 PubMedPubMedCentralCrossRef

19.

Bomeisl PE, Thompson CL, Harris LN, Gilmore HL (2015) Comparison of oncotype DX recurrence score by histologic types of breast carcinoma. Arch Pathol Lab Med 139(12):1546–1549. https://doi.org/10.5858/arpa.2014-0557-OA PubMedCrossRef

20.

Siegelmann-Danieli N, Silverman B, Zick A, Beit-Or A, Katzir I, Porath A (2013) The impact of the Oncotype DX Recurrence Score on treatment decisions and clinical outcomes in patients with early breast cancer: the Maccabi Healthcare Services experience with a unified testing policy. Ecancermedicalscience 7:380. https://doi.org/10.3332/ecancer.2013.380 PubMedPubMedCentralCrossRef

21.

Jambal P, Badtke MM, Harrell JC, Borges VF, Post MD, Sollender GE, Spillman MA, Horwitz KB, Jacobsen BM (2013) Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features. Breast Cancer Res Treat 137(2):431–448. https://doi.org/10.1007/s10549-012-2377-x PubMedCrossRef

22.

Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Manuel CA, Edgerton SM, Harrell JC, Elias A, Sartorius CA (2012) Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat 135(2):415–432. https://doi.org/10.1007/s10549-012-2164-8 PubMedCrossRef

23.

D’Amato NC, Gordon MA, Babbs B, Spoelstra NS, Carson Butterfield KT, Torkko KC, Phan VT, Barton VN, Rogers TJ, Sartorius CA, Elias A, Gertz J, Jacobsen BM, Richer JK (2016) Cooperative dynamics of AR and ER activity in breast cancer. Mol Cancer Res 14(11):1054–1067. https://doi.org/10.1158/1541-7786.MCR-16-0167 PubMedPubMedCentralCrossRef

24.

Korch C, Spillman MA, Jackson TA, Jacobsen BM, Murphy SK, Lessey BA, Jordan VC, Bradford AP (2012) DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol Oncol 127(1):241–248. https://doi.org/10.1016/j.ygyno.2012.06.017 PubMedPubMedCentralCrossRef

25.

Harrell JC, Shroka TM, Jacobsen BM (2017) Estrogen induces c-Kit and an aggressive phenotype in a model of invasive lobular breast cancer. Oncogenesis 6(11):396. https://doi.org/10.1038/s41389-017-0002-x PubMedPubMedCentralCrossRef

26.

Badtke MM, Jambal P, Dye WW, Spillman MA, Post MD, Horwitz KB, Jacobsen BM (2012) Unliganded progesterone receptors attenuate taxane-induced breast cancer cell death by modulating the spindle assembly checkpoint. Breast Cancer Res Treat 131(1):75–87. https://doi.org/10.1007/s10549-011-1399-0 PubMedCrossRef

27.

Harrell JC, Dye WW, Allred DC, Jedlicka P, Spoelstra NS, Sartorius CA, Horwitz KB (2006) Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res 66(18):9308–9315PubMedCrossRef

28.

Goswami CP, Nakshatri H (2013) PROGgene: gene expression based survival analysis web application for multiple cancers. J Clin Bioinform 3(1):22. https://doi.org/10.1186/2043-9113-3-22 CrossRef

29.

Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, Liu ET, Miller L, Nordgren H, Ploner A, Sandelin K, Shaw PM, Smeds J, Skoog L, Wedren S, Bergh J (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7(6):R953–R964. https://doi.org/10.1186/bcr1325 PubMedPubMedCentralCrossRef

30.

Yousef EM, Furrer D, Laperriere DL, Tahir MR, Mader S, Diorio C, Gaboury LA (2017) MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation. Mod Pathol 30(5):682–697. https://doi.org/10.1038/modpathol.2016.231 PubMedCrossRef

31.

Aksoy N, Thornton DJ, Corfield A, Paraskeva C, Sheehan JK (1999) A study of the intracellular and secreted forms of the MUC2 mucin from the PC/AA intestinal cell line. Glycobiology 9(7):739–746PubMedCrossRef

32.

Rose MC, Voynow JA (2006) Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev 86(1):245–278. https://doi.org/10.1152/physrev.00010.2005 PubMedCrossRef

33.

Wittel UA, Goel A, Varshney GC, Batra SK (2001) Mucin antibodies - new tools in diagnosis and therapy of cancer. Front Biosci 6:D1296–D1310PubMedCrossRef

34.

Vokuda RS, Verma SK, Srinivas BH (2018) Tissue Microarray Technology-A Brief Review. Natl J Lab Med 7(1):PR01–PR04

35.

Sonora C, Mazal D, Berois N, Buisine MP, Ubillos L, Varangot M, Barrios E, Carzoglio J, Aubert JP, Osinaga E (2006) Immunohistochemical analysis of MUC5B apomucin expression in breast cancer and non-malignant breast tissues. J Histochem Cytochem 54(3):289–299. https://doi.org/10.1369/jhc.5A6763.2005 PubMedCrossRef

36.

Ookawa K, Kudo T, Aizawa S, Saito H, Tsuchida S (2002) Transcriptional activation of the MUC2 gene by p53. J Biol Chem 277(50):48270–48275. https://doi.org/10.1074/jbc.M207986200 PubMedCrossRef

37.

Valque H, Gouyer V, Gottrand F, Desseyn JL (2012) MUC5B leads to aggressive behavior of breast cancer MCF7 cells. PLoS ONE 7(10):e46699. https://doi.org/10.1371/journal.pone.0046699 PubMedPubMedCentralCrossRef

38.

Valque H, Gouyer V, Husson MO, Gottrand F, Desseyn JL (2011) Abnormal expression of Muc5b in Cftr-null mice and in mammary tumors of MMTV-ras mice. Histochem Cell Biol 136(6):699–708. https://doi.org/10.1007/s00418-011-0872-5 PubMedCrossRef

39.

Garcia EP, Tiscornia I, Libisch G, Trajtenberg F, Bollati-Fogolin M, Rodriguez E, Noya V, Chiale C, Brossard N, Robello C, Santinaque F, Folle G, Osinaga E, Freire T (2016) MUC5B silencing reduces chemo-resistance of MCF-7 breast tumor cells and impairs maturation of dendritic cells. Int J Oncol 48(5):2113–2123. https://doi.org/10.3892/ijo.2016.3434 PubMedCrossRef

40.

Tadesse S, Corner G, Dhima E, Houston M, Guha C, Augenlicht L, Velcich A (2017) MUC2 mucin deficiency alters inflammatory and metabolic pathways in the mouse intestinal mucosa. Oncotarget 8(42):71456–71470. https://doi.org/10.18632/oncotarget.16886 PubMedPubMedCentralCrossRef

41.

Shan YS, Hsu HP, Lai MD, Yen MC, Fang JH, Weng TY, Chen YL (2014) Suppression of mucin 2 promotes interleukin-6 secretion and tumor growth in an orthotopic immune-competent colon cancer animal model. Oncol Rep 32(6):2335–2342. https://doi.org/10.3892/or.2014.3544 PubMedPubMedCentralCrossRef

42.

He YF, Zhang MY, Wu X, Sun XJ, Xu T, He QZ, Di W (2013) High MUC2 expression in ovarian cancer is inversely associated with the M1/M2 ratio of tumor-associated macrophages and patient survival time. PLoS ONE 8(12):e79769. https://doi.org/10.1371/journal.pone.0079769 PubMedPubMedCentralCrossRef

43.

Yonezawa S, Goto M, Yamada N, Higashi M, Nomoto M (2008) Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior. Proteomics 8(16):3329–3341. https://doi.org/10.1002/pmic.200800040 PubMedCrossRef

44.

Hollingsworth MA, Swanson BJ (2004) Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4(1):45–60. https://doi.org/10.1038/nrc1251 PubMedCrossRef

45.

Scully OJ, Bay BH, Yip G, Yu Y (2012) Breast cancer metastasis. Cancer Genom Proteom 9(5):311–320

46.

Hsu HP, Lai MD, Lee JC, Yen MC, Weng TY, Chen WC, Fang JH, Chen YL (2017) Mucin 2 silencing promotes colon cancer metastasis through interleukin-6 signaling. Sci Rep 7(1):5823. https://doi.org/10.1038/s41598-017-04952-7 PubMedPubMedCentralCrossRef

47.

Cardillo MR, Castagna G, Memeo L, De Bernardinis E, Di Silverio F (2000) Epidermal growth factor receptor, MUC-1 and MUC-2 in bladder cancer. J Exp Clin Cancer Res 19(2):225–233PubMed

48.

Utsunomiya T, Yonezawa S, Sakamoto H, Kitamura H, Hokita S, Aiko T, Tanaka S, Irimura T, Kim YS, Sato E (1998) Expression of MUC1 and MUC2 mucins in gastric carcinomas: its relationship with the prognosis of the patients. Clin Cancer Res 4(11):2605–2614PubMed

49.

Jonckheere N, Skrypek N, Van Seuningen I (2014) Mucins and tumor resistance to chemotherapeutic drugs. Biochim Biophys Acta 1846(1):142–151. https://doi.org/10.1016/j.bbcan.2014.04.008 PubMedCrossRef

50.

Leteurtre E, Gouyer V, Rousseau K, Moreau O, Barbat A, Swallow D, Huet G, Lesuffleur T (2004) Differential mucin expression in colon carcinoma HT-29 clones with variable resistance to 5-fluorouracil and methotrexate. Biol Cell 96(2):145–151. https://doi.org/10.1016/j.biolcel.2003.12.005 PubMedCrossRef

Titel: Mucin 2 (MUC2) modulates the aggressiveness of breast cancer
verfasst von: Anna Astashchanka
Thomas M. Shroka
Britta M. Jacobsen
Publikationsdatum: 13.10.2018
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-4989-2

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Mucin 2 (MUC2) modulates the aggressiveness of breast cancer

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Correction to: Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis

Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea

Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens

Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set

Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?

Machine learning for diagnostic ultrasound of triple-negative breast cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie